International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
ID: 347525Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $125K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347525

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-023.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative specifically targets organizations headquartered in low- and lower-middle-income economies, as classified by the World Bank, and encourages collaboration with U.S. institutions to enhance local scientific capabilities. The program anticipates funding approximately 7-8 awards totaling $1.36 million, with a maximum budget of $125,000 per year per project, and applications are due by 5:00 PM local time on August 1, 2025. Interested applicants can find more information and submission guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-23-023-Full-Announcement.html
    RFA-AI-23-023.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has issued a funding opportunity announcement (FOA) titled "International Research in Infectious Diseases" (R01 Clinical Trial Not Allowed). This initiative aims to support research on infectious diseases in resource-constrained foreign countries, with a particular focus on low- and lower-middle-income economies as classified by the World Bank. Applicant organizations must be headquartered in these eligible countries. The FOA encourages collaboration with U.S. institutions and emphasizes capability building in local scientific communities. Applications are due by 5:00 PM local time, with funding anticipated in 2024 for about 7-8 awards totaling $1.36 million, with a maximum budget of $125,000 per year per project. Projects may focus on a variety of infectious diseases but cannot include clinical trials. The application process requires compliance with specific instructions outlined in the announcement, and registration with eRA Commons and Grants.gov is mandatory. The document concludes with details on submission, review, and funding processes to ensure high scientific merit in proposed projects.
    Similar Opportunities
    Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Global Infectious Disease Research Administration Development Award (G11 Clinical Trial Not Allowed), aimed at enhancing the administrative capabilities of research institutions in low- and middle-income countries (LMICs) through advanced training in grants management. This funding opportunity invites eligible institutions to develop comprehensive plans that include a Research Grants Administration/Financial Management Plan, Staff Training Plan, and a Long-term Plan, with the goal of improving oversight and compliance with NIH funding policies. The initiative emphasizes capacity building in resource-limited settings, supporting travel for senior administrators to receive training from experienced U.S. institutions, with project budgets capped at $100,000 annually for a maximum period of two years. Interested applicants should submit their proposals by March 13, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-300.html.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Infectious Diseases Clinical Trials Network (IDCTN)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Infectious Diseases Clinical Trials Network (IDCTN)" aimed at advancing public health through the rapid implementation of clinical trials for infectious diseases. This initiative seeks to establish a network comprising Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC) to evaluate therapeutics, vaccines, diagnostics, and devices, addressing urgent public health needs that standard grant timelines cannot meet. With an estimated total program funding of $29 million, this opportunity is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, and community-based organizations. Interested parties can reach out to Dr. Marina S. Lee at 240-627-3304 or via email at dmidclinicaltrials@niaid.nih.gov for further information, with key deadlines including an estimated synopsis close date of June 11, 2026, and an anticipated award date of March 1, 2027.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infections with multiple pathogens, excluding HIV. This initiative seeks to investigate the mechanisms and epidemiology of cancer linked to various infectious agents, addressing significant gaps in the current understanding of cancer etiology, with a focus on health disparities in underrepresented populations. Eligible applicants include a wide range of entities such as higher education institutions, nonprofits, and foreign organizations, with no budget limit for applications, although strong preliminary data is required. Key deadlines include an earliest submission date of January 5, 2025, and a close date of January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-082.html.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" grant, aimed at enhancing research into the relationship between co-infections and cancer. This initiative encourages exploratory studies that investigate how concurrent or sequential infections by multiple pathogens influence carcinogenesis, with a focus on mechanistic and epidemiological insights rather than clinical trials. The grant supports research that may inform cancer prevention and treatment strategies, particularly concerning infection-related cancers, with a maximum award of $275,000 for a two-year project period. Applications are due starting January 16, 2025, and interested applicants can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-083.html.
    NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity for investigator-initiated Resource-Related Research Projects (R24), specifically excluding clinical trials. This initiative aims to enhance existing high-priority research by supporting resources that provide critical data, materials, tools, or services beneficial to the scientific community, particularly in areas related to immunology and infectious diseases. Eligible applicants include a diverse range of institutions, such as higher education and nonprofit organizations, with proposals due by January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-065.html.
    Limited Competition: International epidemiology Databases to Evaluate AIDS (IeDEA) (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "International epidemiology Databases to Evaluate AIDS (IeDEA) (U01 Clinical Trial Not Allowed)" aimed at continuing support for the HIV IeDEA Consortium. This cooperative agreement is specifically open to renewal applications from existing IeDEA Regional Data Centers, which include institutions such as the Foundation for AIDS Research and Johns Hopkins University, among others. The initiative is crucial for gathering and analyzing HIV clinical and contextual data to address regional and global research priorities related to the HIV epidemic. The estimated total program funding is $20,665,000, with seven awards expected, and interested applicants can reach out to Lori Zimand Abramson at lzimand@niaid.nih.gov or by phone at 240-627-3212 for further information. The application process is anticipated to open with a synopsis posted on August 5, 2025, and the estimated close date for applications is December 3, 2025.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD," aimed at stimulating research related to HIV/AIDS and communication disorders. This initiative encourages applications that address high-priority research areas defined by the NIH Office of AIDS Research, focusing on the impact of HIV on hearing, balance, taste, smell, voice, speech, and language, with a budget limit of $275,000 for a two-year project period. Eligible applicants include a diverse range of institutions and organizations, and only low-risk clinical trials that do not require FDA oversight will be supported. Interested parties can find more information and application details at the NIH grants website, with deadlines for submissions ranging from May 2025 to January 2028.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" aimed at stimulating research related to HIV/AIDS within the National Institute on Deafness and Other Communication Disorders (NIDCD). This initiative encourages applications that address high-priority research areas identified by the NIH Office of AIDS Research, particularly focusing on the intersections of HIV/AIDS with hearing, communication, and associated disorders. Grants of up to $499,999 in direct costs are available for projects lasting up to five years, with no cost-sharing or matching requirements. Interested applicants, including educational institutions and community organizations, must adhere to NIH guidelines and submit their proposals through Grants.gov by the closing date of January 7, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.